Navigation Links
Roche Scientist Recognized for Excellence in Peptide Chemistry
Date:10/7/2009

BOULDER, Colo., Oct. 7 /PRNewswire/ -- Waleed Danho, Ph.D., Distinguished Research Leader at Roche was honored last week as the 2009 recipient of the Meienhofer Award for excellence in peptide chemistry at the international peptide symposium, RCCPS (http://www.rochecolorado.com/PeptideSymp09/). Hosted by Roche Colorado, the company's peptide manufacturing facility in Boulder, RCCPS is the only global conference exclusively dedicated to peptides. For Danho, who has a world-wide reputation as a leader and innovator in the field of peptide chemistry and the application of peptide chemistry to drug discovery, this was the second prestigious award he garnered this year.

"Each year, the world's leading peptide scientists honor one of their own at RCCPS for a lifetime of outstanding achievement," said the symposium's co-chair, Ralph Di Libero. "The selection of Waleed as the 2009 Meienhofer Award recipient is particularly compelling as it speaks volumes to the central role that Roche is playing, through all stages of drug development, at demonstrating the viability of synthetic peptide therapeutics."

This theme was echoed by Danho. "There were many who doubted the viability of synthetic peptides, relegating promising medicinal compounds to the shelf. Roche kept its faith in my vision for the future of peptides and their faith is beginning to bear fruit, with many synthetic peptides now providing meaningful health benefits and many more in the pipeline."

"Of course," concluded Danho, "I accept this tribute with due respect for my colleagues in the peptide field who helped advance the science to its present place of influence in the pharmaceutical industry. That is what makes the Meienhofer Award, receiving it as I did during this premier gathering of peptide scientists, such a meaningful tribute."

Danho joined Roche in 1980 following a well-established career as a noted peptide chemist. He earned his doctorate in 1967 at the prestigious RWTH University of Aachen in Germany where his research led to the first crystalline semi-synthetic insulin. Through his subsequent study of the pancreatic and pituitary hormones of camels, Danho helped discover that lipotropin is a pro-hormone of endorphin.

"I cannot think of anyone more deserving than Waleed to receive the Meienhofer Award," said Nader Fotouhi, Ph.D., Vice President for Discovery Chemistry at Roche in Nutley, New Jersey. Dr. Fotouhi noted that, "Waleed has built on the legacy that Dr. Meienhofer started at Roche and has taken it to a significantly higher level. His drive, enthusiasm, honesty, and experience have been critical to the revival of peptides as a therapeutic modality at Roche."

Applying his knowledge of peptides to his work at Roche, Danho fully dedicated himself to demonstrating the therapeutic potential of peptides and their proficiency as a biological proof of concept tool in drug discovery. Danho's research helped to prove that peptides can selectively interact with specific biologic targets to elicit particular effects. The results of his findings, which are documented in over 200 publications, 16 patents and myriad presentations, laid the groundwork for a number of potential new medicinal therapies, including a promising diabetes treatment.

The list of Danho's accomplishments while at Roche is long, but among the most significant achievements is the investigation of cholecystokinin involvement as a systematic approach to discovering peptide mimetics and enriching the Roche intellectual portfolio on peptide nucleic acids (PNAs). However, he is probably best recognized for his seminal work in male erectile dysfunction (ED). While originally evaluating metanocortin-4 (MC-4) receptor antagonist in the treatment of obesity, Danho's research group recognized that MC-4 had an effect on erectile function, leading to the discovery of a potent and selective peptide that has entered clinical trials.

In recognition of his prestigious career, Danho was honored as a 2009 recipient of the Lifetime Achievement Award from the North Jersey Section of the American Chemical Society in May (http://www.rocheusa.com/newsroom/current/2009/pr2009052701.html).

About RCCPS

RCCPS, the Roche Colorado Corporation Peptide Symposium, is the only global conference exclusively dedicated to peptides. The symposium covers topics ranging from discovery and medicinal chemistry through commercialization. Attendance at RCCPS is composed of a unique mix of academics and scientists focused on developing peptides as commercial therapeutics.

About the Meienhofer Award

The Meienhofer Award is presented for lifetime achievements in the field of peptide research. This annual award is named in honor of Roche scientist, Dr. Johannes Meienhofer, one of the leading peptide chemists of the 20th century and a pioneer of the modern chemical biology field.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About Roche Colorado

Roche Colorado Corporation, a subsidiary of the Roche Group, is a pharmaceutical manufacturing facility located in Boulder, Colorado. Roche Colorado has a workforce of about 300 employees, including chemists, engineers, and manufacturing personnel, who specialize in the production of therapeutic peptides and highly active compounds. The company has received particular acclaim for its work on the anti-HIV drug, Fuzeon® (enfuvirtide), a 36 amino acid peptide that was awarded the 2004 International Prix Galien as the world's most innovative new medicine. Roche Colorado's strong record of achievement in the synthetic peptide field earned it the Biotechnology Company of the Year award from the Colorado Bioscience Association. Learn more at www.rochecolorado.com/peptides.

    Contacts:  John Tayer                         Darien Wilson
               Public Affairs and Communications  Public Affairs
               303-938-6414                       973-562-2232
               John.tayer@roche.com               darien_e.wilson@roche.com

SOURCE Roche


'/>"/>
SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
2. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
3. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
4. Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
7. National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities
8. MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis
9. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
10. Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
11. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... February 22, 2017 Indivumed, GmbH (Indivumed), a ... and The Indian Institute of Technology Madras (IITM), the ... the first Indian national cancer data base and biobank for use ... ... term. The collaboration will include collection of many types of cancer, ...
(Date:2/21/2017)... 2017 Micro Guide Catheters Market: Overview ... Micro Guide Catheters are used ... clinics and ambulatory surgery centers etc. Micro guide ... selection of micro guide catheter depends on the ... body. Micro guide catheters are available in different ...
(Date:2/21/2017)... 2017 Diabetic Shoes Market: Overview Read ... ... a disease, which is marked by high levels of blood ... The disease has become a global epidemic leading to serious ... organs of the body including eyes, kidneys, heart. However, it ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... - the Vector™ Series Multi-Cook Oven offers up to four ovens in one. ... Structured Air Technology™ for unmatched evenness in cooking. Alto-Shaam has partnered with Appliance ...
(Date:2/21/2017)... ... 2017 , ... Robins & Morton celebrated the grand opening ... 21. , The celebration began with a ribbon cutting event at 10:30 a.m., ... and tribal leadership. , Choctaw Nation Durant Regional Medical Clinic is a ...
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... As ... United States according to the American Society of Plastic Surgeons. Some patients want to ... the functionality of their nose and improve their breathing ability. The team at ...
(Date:2/21/2017)... ... 2017 , ... American Veterinarian™, the premier multimedia provider of ... first bi-monthly issue of 2017 in February. The inaugural issue will offer expert ... , In making the announcement, American Veterinarian™ Publisher Chris Hennessy said, “We ...
(Date:2/21/2017)... California (PRWEB) , ... February 21, 2017 , ... ... world with over 50,000 participants. The connected care demonstration spanned multiple health ... the National Coordinator, roughly 30% of providers have no Health Information Exchange outside ...
Breaking Medicine News(10 mins):